Clinical trial
A Two Comparator, Controlled Phase 3 Study of OM3 Tear Formulation Versus OPTIVE ADVANCED Unit Dose and OPTIVE Unit Dose Eye Drops in Patients With and Without Evaporative Dry Eye.
NCT02871440 is registered in ClinicalTrials.gov with The University of New South Wales as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two Comparator, Controlled Phase 3 Study of OM3 Tear Formulation Versus OPTIVE ADVANCED Unit Dose and OPTIVE Unit Dose Eye Drops in Patients With and Without Evaporative Dry Eye.
- Lead sponsor
- The University of New South Wales
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 19, 2016
- Completion date
- September 18, 2017
- Enrollment
- 40 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.